ReviewThe Yale journal of biology and medicine2017
A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers.
Review in The Yale journal of biology and medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Comprehensive multi-omics analysis uncovers potential risks of aged sperm on offspring development after short-term storage.BMC biology · 2025Article
- Angioplasty induces epigenomic remodeling in injured arteries.Life science alliance · 2022Article
- Polycomb Repressive Complexes: Shaping Pancreatic Beta-Cell Destiny in Development and Metabolic Disease.Frontiers in cell and developmental biology · 2022Review
- Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Review
- BRD2 regulation of sigma-2 receptor upon cholesterol deprivation.Life science alliance · 2021Article
- The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation.Cellular signalling · 2019Article
- Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors.Genes · 2018Review
- Cardiac ageing: extrinsic and intrinsic factors in cellular renewal and senescence.Nature reviews. Cardiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent progress in epigenetic research has made a profound influence on pharmacoepigenomics, one of the fastest growing disciplines promising to provide new epi-drugs for the treatment of a broad range of diseases. Histone acetylation is among the most essential chromatin modifications underlying the dynamics of transcriptional activation. The acetylated genomic regions recruit the BET (bromodomain and extra-terminal) family of bromodomains (BRDs), thereby serving as a molecular scaffold in establishing RNA polymerase II specificity. Over the past several years, the BET epigenetic readers have become the main targets for drug therapy. The discovery of selective small-molecule compounds with capacity to inhibit BET proteins has paved a path for developing novel strategies against cancer, cardiovascular, skeletal, and inflammatory diseases. Therefore, further research into small chemicals impeding the regulatory activity of BRDs could offer therapeutic benefits for many health problems including tumor growth, heart disease, oral, and bone disorders.
Indexed as
Identifiers
28356894PMC5369046W3023543248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.